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SUMMARY
Background
In a phase 2 study, mongersen, an oral antisense oligonucleotide targeting
Smad7, was effective in inducing clinical remission in approximately 60%
of patients with active Crohn’s disease (CD).
Aim
In a post hoc analysis to evaluate those patient disease characteristics that
may have inﬂuenced the efﬁcacy and safety of mongersen therapy.
Methods
Patients with steroid-dependent/resistant, active CD were randomised to
mongersen 10, 40 or 160 mg/day or placebo for 2 weeks; patients were fol-
lowed for 10 weeks. Clinical remission [Crohn’s Disease Activity Index
(CDAI) score <150] and clinical response (CDAI score reduction ≥100
points) were assessed at weeks 2, 4 and 12 for these subgroups: disease
duration <5/≥5 years, human serum C-reactive protein (hsCRP) <3/≥3 mg/
L, and CDAI at baseline ≤260/>260. Additional patient baseline and disease
characteristics were explored.
Results
Clinical remission and response rates were signiﬁcantly higher in patients receiv-
ing mongersen 40 and 160 mg/day but not 10 mg/day vs. placebo and indepen-
dent of disease duration and hsCRP. Patients with baseline CDAI ≤260 had
signiﬁcantly higher remission rates with 40 and 160 mg/day. In patients with
baseline CDAI >260, remission rates were statistically greater with 160 mg/day
and numerically better with 40 mg/day vs. placebo. Adverse event rates were
similar across treatment groups. Mongersen was safe and well tolerated.
Conclusions
Patients with higher CDAI scores achieved clinical remission most fre-
quently with the highest mongersen dose. Disease duration and baseline
human serum C-reactive protein did not appear to signiﬁcantly impact efﬁ-
cacy of mongersen in this study (EudraCT Number: 2011-002640-27.)
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INTRODUCTION
Crohn’s disease (CD) is a chronic condition charac-
terised by a segmental, transmural inﬂammation, which
can affect any part of the alimentary tract, even though
lesions are more common in the terminal ileum and
right colon. CD-related inﬂammation is responsible for a
variety of symptoms/signs and development of local
complications and extraintestinal manifestations.1, 2
Smad7, an intracellular protein that binds TGF-b
receptor and prevents TGF-b1-associated and SMAD-
associated signalling in CD, has been identiﬁed as a
novel target for suppression of CD-associated inﬂamma-
tion.3 In a phase 1 trial, mongersen (GED-0301), an oral
formulation containing the Smad7 antisense
oligonucleotide, demonstrated a rapid and durable clini-
cal beneﬁt in patients with active CD, conﬁrming the
role of Smad7 in the inﬂammatory process of CD.4, 5
The results of a subsequent phase 2 study of mongersen
in patients with active CD (IGON1 study) were recently
reported.6 A marked treatment effect was observed in
this study, with clinical remission rates [Crohn’s Disease
Activity Index (CDAI) <150 points at week 2 and main-
tained for 2 weeks] in 55% and 65% of patients treated
with 40 and 160 mg/day, respectively, for 2 weeks.6
Subgroup analyses from prospective, randomised,
controlled trials in patients with active CD indicate that
various patient disease characteristics and demographics
can affect clinical outcomes.7–12 In particular, patients
with a shorter duration of CD achieve greater clinical
beneﬁt compared with patients with longer disease dura-
tion, and treatment with biologics and/or immunosup-
pressive drugs early in duration of CD leads to higher
steroid-free clinical remission rates.13 Similarly, greater
CD activity at baseline may negatively inﬂuence the
efﬁcacy of established therapy.10–12, 14
Because these and a number of other patient disease
characteristics and demographics may impact patient
outcomes, we retrospectively explored the impact of
duration and disease activity of CD along with sex, body
mass index, smoking status, history of CD-related
intestinal resection, steroid status and immunosuppres-
sant use at baseline on the efﬁcacy and safety of
mongersen treatment.
MATERIALS AND METHODS
Study design
Data used for this post hoc analysis were from IGON1,6
a previously reported, multicentre, randomised, double-
blind, placebo-controlled study of mongersen (10, 40, or
160 mg/day) in patients with active CD (CDAI score of
220–400) who were steroid-dependent and/or steroid-
resistant, as deﬁned by recent guidelines of the European
Crohn’s and Colitis Organisation,15 and had inﬂamma-
tory lesions in the terminal ileum and/or right colon.
The study protocol for IGON1 was approved by the
Institutional Review Board or Ethics Committee at each
of the 17 study centres in Italy and Germany. Written
informed consent was obtained from patients before they
underwent screening for eligibility; eligible patients
underwent randomisation between September 2011 and
June 2013 (EudraCT number: 2011-002640-27).
Patient sample and clinical assessments
For this analysis, patients were divided into the following
subgroups: disease duration since diagnosis at baseline
<5 years or ≥5 years, normal (<3 mg/L) or abnormal
(≥3 mg/L) human serum C-reactive protein (hsCRP)
value at baseline, and CDAI ≤260 or >260 at baseline.
The CDAI categories were selected in order to have a
sufﬁcient distribution of patients in each group for a
meaningful analysis and to differentiate patients with
moderate disease from those with more severe disease.
The primary analysis for these subgroups was the intent-
to-treat population, deﬁned as all randomised patients,
regardless of response status, who received at least one
dose of study drug. The percentages of patients with
CDAI <150 (clinical remission) and those achieving clin-
ical response (CDAI decrease by 100 points compared
with baseline) were evaluated for mongersen and placebo
patients in each disease duration and severity subgroup
at weeks 2, 4 and 12. Additional categories evaluated
included male or female, body mass index <25 or
≥25 kg/m2, smoking status, history of CD-related intesti-
nal resection, steroid status (refractory or dependent)
and immunosuppressant use. Safety data were analysed
according to the same classes of disease duration and
severity for all patients who received at least one dose of
study drug.
Statistical analysis
Baseline characteristics among the subgroups were com-
pared by means of descriptive methods. In the analysis
of clinical remission/response, patients who dropped out
or had missing data were considered nonresponders.
Within each disease duration and severity subgroup, the
fractions of patients achieving clinical remission or
response were compared between each mongersen dose
and placebo at each time point using an unconditional
exact test. All treatment comparisons used two-sided
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tests, and statistical signiﬁcance was set at P < 0.05.
Logistic regression analyses, along with receiver operat-
ing characteristic analyses, were performed to evaluate
the impact of each of the subgroup variables as a contin-
uous variable on clinical remission and response.
RESULTS
Baseline demographics and clinical characteristics by
disease duration and severity
Of the 166 patients assigned to receive one of three
mongersen doses or placebo, six had protocol violations
and missing data at week 2 and were classiﬁed as
nonresponders. The remaining 160 patients (96.4%)
completed the 2-week treatment and 4-week study visit,
while 138 patients (83.1%) completed the 12-week study
visit. The reasons for patients withdrawing from the
trial after week 4 have been reported previously.6
Table 1 summarises the baseline demographics and dis-
ease characteristics of the patients according to disease
duration, deﬁned as time since CD diagnosis, baseline
hsCRP value and CDAI score. Baseline mean age, sex,
mean body mass index and smoking status were similar
across the six subgroups. The rate of CD-related
surgery was greater in the subgroups of patients
with disease duration ≥5 years [60/96 (62.5%) vs. 10/69
(14.5%); P < 0.0001] and patients with hsCRP <3 mg/L
[39/64 (60.9%) vs. 32/102 (31.4%); P = 0.0002].
Clinical remission
Overall proportions of patients with clinical remission
(deﬁned as CDAI <150) were signiﬁcantly higher with
mongersen 160 and 40 mg/day compared with placebo,
and this was evident for each disease duration subgroup
at weeks 2, 4 and 12 (Figure 1a and b). Similar remis-
sion rates between mongersen 160 and 40 mg/day or
between mongersen 10 mg/day and placebo were
observed (Figure 1a and b).
The week 2 remission rate in patients treated with
mongersen 160 mg/day was greater than that seen in
placebo patients, and this was evident in both sub-
groups of patients with either normal or abnormal
hsCRP value at baseline (Figure 2a and b). At the same
time point, the remission rate for the mongersen
40 mg/day patients with normal baseline hsCRP values
was signiﬁcantly different compared with placebo.
While the remission rates in patients with abnormal
hsCRP values were numerically greater than placebo
(50% vs. 24%, respectively) at week 2, the results were
not signiﬁcantly different (Figure 2a and b). Compared
with placebo, signiﬁcantly greater percentages of
patients treated with mongersen 160 or 40 mg/day, but
not 10 mg/day, achieved clinical remission in the sub-
groups of patients with either normal or abnormal
hsCRP value at baseline, and this was evident at weeks
4 and 12 (Figure 2a and b).
In each subgroup of patients with CDAI score ≤260
or >260, patients treated with mongersen 160 mg/day
had signiﬁcantly greater remission rates compared with
placebo patients, and this was evident at each time point
(Figure 3a and b). Moreover, at each time point, in the
subgroup of patients with CDAI ≤260, rate of remission
was signiﬁcantly greater in the mongersen 40 mg/day
group than in the placebo group (Figure 3a), while in
the subgroup of patients with CDAI >260, the difference
between the mongersen 40 mg/day and placebo groups
was evident only at week 4 (Figure 3b). Among the other
patient characteristics and demographics evaluated, dif-
ferences in clinical remission were seen in the mongersen
160 mg/day group compared with the placebo group at
Table 1 | Demographics and clinical characteristics of the participants to IGON1 study in relation to disease duration,
baseline hsCRP value and baseline CDAI score
Disease duration hsCRP CDAI
<5 years ≥5 years <3 mg/L ≥3 mg/L ≤260 >260
Patients, n (%)* 69/166 (41.6) 96/166 (57.8) 64/166 (38.6) 102/166 (61.4) 99/166 (59.6) 67/166 (40.4)
Age, mean (years) 39.5 44.6 43.0 42.3 44.3 39.9
Female, n (%) 34/69 (49.3) 50/96 (52.1) 34/64 (53.1) 51/102 (50.0) 47/99 (47.5) 38/67 (56.7)
BMI, mean (kg/m2) 23.6 22.8 22.1 23.9 23.8 22.3
Current smoker, n (%) 25/69 (36.2) 36/96 (37.5) 23/64 (35.9) 39/102 (38.2) 38/99 (38.4) 24/67 (35.8)
History of CD-related
intestinal resection, n (%)
10/69 (14.5) 60/96 (62.5) 39/64 (60.9) 32/102 (31.4) 37/99 (37.4) 34/67 (50.7)
* Disease duration data were missing for one patient.
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Figure 1 | Clinical remission,
deﬁned as a Crohn’s Disease
Activity Index (CDAI) score
<150, at weeks 2, 4 and 12 by
disease duration <5 years (a)
or ≥5 years (b) for all
randomised patients (intent-
to-treat population) in a post
hoc analysis from IGON1,6 a
previously reported,
multicentre, randomised,
double-blind, placebo-
controlled study of mongersen
(10, 40, or 160 mg/day) in
patients with active Crohn’s
disease (baseline CDAI score
220–400). *P ≤ 0.02;
†P ≤ 0.0006; ‡P = 0.002 vs.
placebo.
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Figure 2 | Clinical remission,
deﬁned as a Crohn’s Disease
Activity Index (CDAI) score
<150, at weeks 2, 4 and 12 by
baseline human serum C-
reactive protein (hsCRP)
values <3 mg/L (a) or
≥3 mg/L (b) for all
randomised patients (intent-
to-treat population) in a post
hoc analysis from IGON1.6
*P < 0.02; †P < 0.006;
‡P ≤ 0.0005 vs. placebo.
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all time periods, regardless of subgroup, except in cur-
rent smokers and males (nonsigniﬁcant at week 2) who
had greater remission rates.
Clinical response
The overall pattern of results for clinical response-100
rates by disease duration, baseline hsCRP value, and
baseline CDAI score followed the same pattern as the
results for clinical remission. However, in contrast to the
clinical remission ﬁndings, greater response rates were
seen for both the mongersen 160 and 40 mg/day dose
groups, compared with the placebo group, in each sub-
group of patients with CDAI score ≤260 or >260. Clini-
cal response rates at weeks 2, 4 and 12 as a function of
disease duration, baseline hsCRP and CDAI score are
shown in Table 2.
Logistic regression
Logistic regression models conﬁrmed that the baseline
CDAI score, and not the disease duration or baseline
hsCRP, inﬂuenced the likelihood of clinical remission
with mongersen. Throughout the CDAI range, a higher
probability of clinical remission at week 4 was demon-
strated in patients in the 160 mg/day group compared
with the other treatment groups in this model (Figure 4).
The ﬁndings from the logistic regression models were
corroborated with receiver operating characteristic analy-
ses where the baseline CDAI score of 260 corresponded
to the optimal cut-off for prediction of clinical remission,
in contrast to the baseline hsCRP and disease duration,
which had no impact on clinical remission.
Adverse events by disease duration and severity
The overall rate of adverse events (AEs) did not differ
between patients treated with mongersen and those
receiving placebo. The numbers of patients who reported
an AE and the type of AE have been previously
described.6 Placebo patients tended to have greater rates
of AEs in the subgroups with baseline hsCRP value
>3 mg/L and baseline CDAI score >260 compared to the
corresponding subgroups with hsCRP value <3 mg/L
and CDAI score ≤260 (Table 3).
DISCUSSION
In this post hoc analysis of all participants in the IGON1
study, disease duration and baseline hsCRP did not
appear to signiﬁcantly impact the efﬁcacy of mongersen.
Additionally, signiﬁcantly higher clinical remission and
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Figure 3 | Clinical remission,
deﬁned as a Crohn’s Disease
Activity Index (CDAI) score
<150, at weeks 2, 4 and 12 by
baseline Crohn’s Disease
Activity Index (CDAI) scores
≤260 (a) or >260 (b) for all
randomised patients (intent-
to-treat population) in a post
hoc analysis from IGON1.6
*P ≤ 0.01; †P ≤ 0.001 vs.
placebo.
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response rates were observed with mongersen 160 and
40 mg/day compared with the placebo group in most
subgroups, while there was no difference between the
mongersen 10 mg/day group and the placebo group.
Overall, these statistical differences were seen at each
time point and were not inﬂuenced by the disease dura-
tion. These ﬁndings differ from previous data generated
from trials with inﬂiximab, adalimumab and cer-
tolizumab in which shorter disease duration was signiﬁ-
cantly associated with greater likelihood to induce and
maintain remission in CD.10, 11, 14, 16 The reason for
such a different response to these treatments is unknown
but could reﬂect the dominant expression of the phar-
macologic target in the gut of patients because it is
known that TNF production can change during CD
course while Smad7 expression is persistently elevated in
patients with early and established disease.3 In this con-
text it is, however, noteworthy that the association
between the disease duration and therapeutic efﬁcacy of
biologics in CD has been inconsistent.7, 9 For example,
in inﬂiximab-resistant patients, no association was found
between disease duration and induction of clinical remis-
sion with certolizumab at week 26 in the WELCOME
study.17 Similarly, in the ENACT-2 study, the effect of
natalizumab on the rates of remission at 6 and
12 months was not affected by disease duration.
Table 2 | Proportion of patients achieving a clinical response at weeks 2, 4 and 12 as a function of disease duration,
baseline hsCRP value and baseline CDAI score
Disease duration hsCRP CDAI
<5 years ≥5 years <3 mg/L ≥3 mg/L ≤260 >260
Clinical response at 2 weeks
Placebo, n (%) 6/16 (37.5) 5/26 (19.2) 3/17 (17.6) 8/25 (32.0) 6/20 (30.0) 5/22 (22.7)
Mongersen 10
mg/day, n (%)
3/12 (25.0) 6/29 (20.7) 3/14 (21.4) 6/27 (22.2) 3/24 (12.5) 6/17 (35.3)
Mongersen 40
mg/day, n (%)
9/22 (40.9) 8/17 (47.1) 12/18 (66.7)** 6/22 (27.3) 12/28 (42.9) 6/12 (50.0)
Mongersen 160
mg/day, n (%)
11/19 (57.9) 17/24 (70.8)** 11/15 (73.3)** 17/28 (60.7)* 14/27 (51.9) 14/16 (87.5)***
Clinical response at 4 weeks
Placebo, n (%) 3/16 (18.8) 4/26 (15.4) 3/17 (17.6) 4/25 (16.0) 4/20 (20.0) 3/22 (13.6)
Mongersen 10
mg/day, n (%)
3/12 (25.0) 12/29 (41.4)* 6/14 (42.9) 9/27 (33.3) 8/24 (33.3) 7/17 (41.2)
Mongersen 40
mg/day, n (%)
14/22 (63.6)* 8/17 (47.1)* 10/18 (55.6)* 13/22 (59.1)** 16/28 (57.1)* 7/12 (58.3)*
Mongersen 160
mg/day, n (%)
14/19 (73.7)** 17/24 (70.8)*** 12/15 (80.0)** 19/28 (67.9)*** 17/27 (63.0)** 14/16 (87.5)***
Clinical response at 12 weeks
Placebo, n (%) 4/16 (25.0) 7/26 (26.9) 5/17 (29.4) 6/25 (24.0) 6/20 (30.0) 5/22 (22.7)
Mongersen 10
mg/day, n (%)
3/12 (25.0) 12/29 (41.4) 6/14 (42.9) 9/27 (33.3) 6/24 (25.0) 9/17 (52.9)
Mongersen 40
mg/day, n (%)
13/22 (59.1)* 14/17 (82.4)** 13/18 (72.2)* 15/22 (68.2)** 21/28 (75.0)** 7/12 (58.3)*
Mongersen 160
mg/day, n (%)
12/19 (63.2)* 19/24 (79.2)** 13/15 (86.7)** 18/28 (64.3)** 17/27 (63.0)* 14/16 (87.5)***
*P < 0.05; **P ≤ 0.005; ***P < 0.0001 vs. placebo.
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Figure 4 | Logistic regression model for clinical
remission, deﬁned as a Crohn’s Disease Activity Index
(CDAI) score <150, at week 4 by baseline CDAI score.
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This analysis shows also that the efﬁcacy of
mongersen 160 and 40 mg/day treatment on clinical
remission and clinical response did not appear to be
signiﬁcantly inﬂuenced by baseline hsCRP value as
patients with either normal or abnormal hsCRP value
responded equally to the drug. HsCRP is a biomarker
of mucosal inﬂammation in CD, and patients with
higher hsCRP values are more likely to beneﬁt from
therapy with biologics. The inclusion criteria limited
the enrolment of patients to those with known disease
only in the terminal ileum and/or right colon, and
there is evidence that active inﬂammation in the ter-
minal ileum is not necessarily accompanied by elevated
hsCRP values, thus providing an explanation of why
the baseline hsCRP value may not inﬂuence the thera-
peutic effect of mongersen. These ﬁndings suggest that
baseline hsCRP may not be determinative in identify-
ing patients who are responsive to mongersen, even
though this point must be further addressed in larger
clinical trials.
In the group of patients receiving mongersen 160 mg/
day, there was no association between induction of clini-
cal remission/response and baseline CDAI score, in con-
trast to the 40 mg/day dose, which demonstrated a
higher remission rate in the subgroup of patients with
baseline CDAI ≤260. These associations were conﬁrmed
by logistic regression analysis, which suggests that
patients with greater CDAI may need the highest dose of
the drug to achieve remission.
There are some limitations of the data presented. This
was a post-hoc analysis and patients enrolled in the
IGON1 study were not randomised taking into account
the disease duration and severity. The cut-off selected to
classify disease duration from the time of diagnosis in
two major subgroups is similar to that proposed in other
studies, but it is arbitrary and does not take into
consideration the fact that some patients may be
asymptomatic for long periods before being diagnosed
with CD. The same criticism can be applied to the CDAI
threshold adopted to differentiate patients with moderate
(220‒260) vs. more severe disease (>260).
In summary, this study suggests that the clinical
beneﬁt seen in patients treated with mongersen 40 or
160 mg/day might not be inﬂuenced by disease duration
and baseline hsCRP, while the mongersen 160 mg/day
dose is necessary to control clinical activity in patients
with more severe disease. These results are extremely
useful for designing the future phase 3 trials with
mongersen.
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Table 3 | Total number of adverse events as a function of disease duration, baseline hsCRP value and baseline CDAI
score
Disease duration hsCRP CDAI
<5 years ≥5 years <3 mg/L ≥3 mg/L ≤260 >260
Placebo, n (%) 10/16 (63) 18/26 (69) 7/17 (41) 21/25 (84) 10/20 (50) 18/22 (82)
Mongersen 10 mg/day, n (%) 5/12 (52) 15/29 (52) 7/14 (50) 13/27 (48) 8/24 (33) 12/17 (71)
Mongersen 40 mg/day, n (%) 12/22 (55) 12/17 (71) 11/18 (61) 14/22 (64) 17/28 (61) 8/12 (67)
Mongersen 160 mg/day, n (%) 12/19 (63) 9/24 (38) 4/15 (27) 17/28 (61) 15/27 (56) 6/16 (38)
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